The co-delivery of CXCR4-targeted NPs with MEK inhibitor and sorafenib in HCC can increase the feasibility of dual RAF/MEK inhibition to overcome sorafenib treatment evasion in HCC. Here, CXCR4 is linked to hepatocellular carcinoma.